Memorial Sloan Kettering Cancer Center

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 1884-01-01

Employees: 10K

Market Cap: -

Website: http://www.mskcc.org

Clinical Trials

ABI-007 in Treating Patients With Chemotherapy-Naïve Stage IV Non-Small Cell Lung Cancer

Phase 1

Completed

Conditions: Lung Cancer

First Posted Date: 2004-02-11

Last Posted Date: 2013-11-06

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 64

Registration Number: NCT00077246

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

Irinotecan and Carboplatin as Upfront Window Therapy in Treating Patients With Newly Diagnosed Intermediate-Risk or High-Risk Rhabdomyosarcoma

Phase 2

Active, not recruiting

Conditions: Sarcoma

Interventions: Biological: filgrastim
Drug: carboplatin
Drug: cyclophosphamide
Drug: dexrazoxane hydrochloride
Drug: doxorubicin hydrochloride
Drug: etoposide
Drug: ifosfamide
Drug: irinotecan hydrochloride
Drug: vincristine sulfate
Procedure: conventional surgery
Radiation: radiation therapy

First Posted Date: 2004-02-11

Last Posted Date: 2024-11-04

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 65

Registration Number: NCT00077285

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

Epothilone D as Second-Line Treatment for Patients With Advanced or Metastatic Refractory Colorectal Cancer

Phase 2

Completed

Conditions: Colorectal Cancer

First Posted Date: 2004-02-11

Last Posted Date: 2013-01-16

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Registration Number: NCT00077259

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

Diet and PSA Levels in Patients With Prostate Cancer

Phase 3

Completed

Conditions: Prostate Cancer

First Posted Date: 2004-02-09

Last Posted Date: 2013-06-26

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 154

Registration Number: NCT00003367

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

Photodynamic Therapy in Treating Patients With Cancer of the Bile Duct, Gallbladder, or Pancreas

Phase 2

Completed

Conditions: Extrahepatic Bile Duct Cancer
Gallbladder Cancer
Liver Cancer
Pancreatic Cancer

First Posted Date: 2004-02-09

Last Posted Date: 2013-03-04

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 4

Registration Number: NCT00003923

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

Combination Chemotherapy and Radiation Therapy in Treating Patients With Colorectal Cancer

Phase 1

Completed

Conditions: Colorectal Cancer

First Posted Date: 2004-02-06

Last Posted Date: 2013-12-19

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 30

Registration Number: NCT00002801

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

Combination Chemotherapy, Radiation Therapy, and Peripheral Stem Cell Transplantation in Treating Patients With Stage III or Stage IV Mantle Cell Lymphoma

Phase 1

Completed

Conditions: Lymphoma

First Posted Date: 2004-01-23

Last Posted Date: 2013-06-24

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 24

Registration Number: NCT00003541

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

TLK286 in Treating Patients With Advanced Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

Phase 2

Completed

Conditions: Fallopian Tube Cancer
Ovarian Cancer
Primary Peritoneal Cavity Cancer

First Posted Date: 2004-01-14

Last Posted Date: 2013-06-26

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Registration Number: NCT00022347

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

Celecoxib in Treating Patients With Precancerous Lesions of the Mouth

Phase 2

Completed

Conditions: Head and Neck Cancer

First Posted Date: 2004-01-07

Last Posted Date: 2013-01-16

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Registration Number: NCT00014404

Locations: 🇺🇸
University of Texas - MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
🇺🇸
Weill Medical College of Cornell University, New York, New York, United States

Suberoylanilide Hydroxamic Acid in Treating Patients With Advanced Solid Tumors That Have Not Responded to Previous Therapy

Phase 1

Completed

Conditions: Leukemia
Lymphoma
Multiple Myeloma and Plasma Cell Neoplasm
Prostate Cancer
Small Intestine Cancer
Unspecified Adult Solid Tumor, Protocol Specific

First Posted Date: 2003-12-17

Last Posted Date: 2013-06-19

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Registration Number: NCT00005634

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy